🔍
Search Results - joseph+barbi
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy
Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...
Published: 3/14/2025
|
Inventor(s):
Drew Pardoll
,
Hong Yu
,
Joseph Barbi
,
Fan Pan
,
Charles Drake
Keywords(s):
Antibodies
,
Autoimmune Diseases
,
Biologics
,
Cancers
,
Combination
,
Disease Indication
,
Inflammatory Disorders
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations > Autoimmunity
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists
Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...
Published: 3/13/2025
|
Inventor(s):
Drew Pardoll
,
Joseph Barbi
,
Fan Pan
,
Hong Yu
,
Ching-Tai Huang
,
Xiaoyu Pan
,
Charles Drake
,
Jonathan Powell
Keywords(s):
Antibodies
,
Biologics
,
Cancers
,
Disease Indication
,
Immunotherapy
,
Infectious Diseases
,
Single
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Infectious Diseases
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
Targeting YAP Activity in Combination with Immunomodulation to Alter Regulatory T Cell-mediated Immune Regulation in order to Treat Cancer
TITLE: INHIBITION OF YAP FOR BREAKING TUMOR IMMUNE TOLERANCECASE NUMBER: C13353UNMET NEEDRegulatory T cells (Tregs) play critical roles in maintaining self-tolerance and homeostasis by suppressing the activation and function of other immune cells. At the same time, the immune-dampening effects of Tregs can inhibit the development...
Published: 3/13/2025
|
Inventor(s):
Benjamin Park
,
Drew Pardoll
,
Duojia Pan
,
Joseph Barbi
,
Fan Pan
Keywords(s):
Biomarker
,
Cancers
,
Disease Indication
,
Mechanism-of-action Biomarker
,
Target
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum